The Federal Trade Commission (FTC) is supporting Amneal Pharmaceuticals in its ongoing efforts to have Teva Pharmaceutical Industries’ inhaler patents removed from the U.S. Food and Drug Administration’s Orange Book. The FTC informed the Federal Circuit that a lower court’s decision, which ruled that Teva’s patents did not meet the requirements to be listed in the Orange Book, was correct. The legal contention revolves around whether Teva’s patents fulfill the criteria mandated for inclusion in this regulatory registry.
For more detailed information, you can access the original article on Law360.